Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lily, O
Right arrow Articles by Ford, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lily, O
Right arrow Articles by Ford, H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Multiple Sclerosis, Vol. 12, No. 6, 808-813 (2006)
DOI: 10.1177/1352458506070946
© 2006 SAGE Publications

Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment

O Lily

Neurosciences Centre, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK, oliver.lily{at}leedsth.nhs.uk

E McFadden

Neurosciences Centre, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK

E Hensor

Neurosciences Centre, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK

M Johnson

Neurosciences Centre, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK

H Ford

Neurosciences Centre, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK

Disease specific quality of life was measured in the Leeds Multiple Sclerosis (MS) Treatment Programme (n-/210) using the self-report Leeds MS Quality of Life (LMSQoL) scale. The results showed a significant and sustained increase in quality of life associated with ‘disease modifying’ treatment. This contrasts with the Expanded Disability Status Scores (EDSS), which showed no measurable improvement. An increase in the LMSQoL score did not correlate with baseline age, disease duration, disability or number of prior relapses. There was no significant difference in treatment effect between relapsing-remitting and secondary progressive MS patients, or between patients receiving different products. However, patients with a poor quality of life at baseline showed the most benefit from treatment. Those who had their treatment stopped due to progression, side-effects or lack of effect had significantly lower LMSQoL scores on treatment. In this study, the LMSQoL scale was responsive to change and was easy to administer in a clinical setting.

Key Words: beta-interferon • Expanded Disability Status Scores • glatiramer acetate • Leeds MS Quality of Life scale • multiple sclerosis • quality of life


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?